Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.

Oncotarget - 30 Mar 2015

Li Jinsong, Deng Huayun, Hu Meichun, Fang Yuanzhang, Vaughn Amanda, Cai Xiaopan, Xu Leqin, Wan Wei, Li Zhenxi, Chen Shijie, Yang Xinghai, Wu Song, Xiao Jianru

Abstract excerpt

The epidermal growth factor receptor (EGFR) is a therapeutic target (oncotarget) in NSCLC. Using in vitro EGFR kinase activity system, we identified a novel small molecule, WB-308, as an inhibitor of EGFR. WB-308 decreased NSCLC cell proliferation and colony formation, by causing G2/M arrest and apoptosis. Furthermore, WB-308 inhibited the engraft tumor growths in two animal models in vivo (lung orthotopic...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to G2 Phase Cell Cycle Checkpoints
Share to Gefitinib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mitogen-Activated Protein Kinase 1

Share to Mitogen-Activated Protein Kinase 3

Share to Molecular Docking Simulation

Share to Quinazolines

Share to Tumor Burden

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 25730907
DOI: 10.18632/oncotarget.3155
PMCID: PMC4466647

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibition of non-small cell lung cancer (NSCLC) growth by a novel small molecular inhibitor of EGFR.PMID 25730907Read ↗

EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer.Semantic proximity Read ↗

Parthenolide inhibits the growth of non-small cell lung cancer by targeting epidermal growth factor receptorSemantic proximity Read ↗

STAT3 inhibitor BBI608 enhances the antitumor effect of gefitinib on EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

Epidermal growth factor receptor mutations in patients with non-small cell lung cancer.Semantic proximity Read ↗

TAE226, a Bis-Anilino Pyrimidine Compound, Inhibits the EGFR-Mutant Kinase Including T790M Mutant to Show Anti-Tumor Effect on EGFR-Mutant Non-Small Cell Lung Cancer Cells.Semantic proximity Read ↗

Long non-coding RNA BC087858 induces non-T790M mutation acquired resistance to EGFR-TKIs by activating PI3K/AKT and MEK/ERK pathways and EMT in non-small-cell lung cancer.Semantic proximity Read ↗

Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer.Semantic proximity Read ↗

244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.Semantic proximity Read ↗

Knockdown of the epidermal growth factor receptor gene to investigate its therapeutic potential for the treatment of non-small-cell lung cancers.Semantic proximity Read ↗

Combination of Huanglian Jiedu Decoction and erlotinib delays growth and improves sensitivity of EGFR‑mutated NSCLC cells in vitro and in vivo via STAT3/Bcl‑2 signaling.Semantic proximity Read ↗

Effect of almonertinib on the proliferation, invasion, and migration in non-small cell lung cancer cells.Semantic proximity Read ↗

Epidermal growth factor receptor inhibition and non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.